狄诺塞麦怎么注射呢？

It is a bone resorption inhibitor with a unique mechanism of action. It specifically targets receptor activator of nuclear factor kappa B (RANK) ligand, inhibits the activation and development of osteoclasts, reduces bone resorption, and increases bone density. Denosumab (Prolia) is a prescription cancer drug that has certain toxic and side effects. It needs to be used under the guidance of a doctor with experience in drug use. How to inject denosumab?

Denosumab can only be given by subcutaneous injection, not by intravenous infusion, intramuscular infusion or intradermal injection. Bone metastases from solid tumors: Denosumab 120 mg subcutaneously in the upper arm, thigh, or abdomen every four weeks. Giant cell tumor of bone: 120 mg denosumab subcutaneously every four weeks. An additional 120 mg of denosumab was administered on days 8 and 15 during the first month of treatment. Malignant hypercalcemia: 120 mg denosumab subcutaneously every four weeks, followed by 120 mg denosumab on days 8 and 15 during the first month of treatment. Denosumab is injected subcutaneously in the upper arm, thigh, or abdomen.

Visually inspect for particulate matter and discoloration before administration. The solution should appear clear, colorless to pale yellow, and may contain trace amounts of translucent to white protein particles. Do not use if discolored or turbid, or if the solution contains many particles or foreign particulate matter.

Before administration, remove from refrigerator to room temperature (up to 25°C/77°F); generally takes 15-30 minutes; do not warm in any other way, and people with latex sensitivities should not use the gray needle cap on disposable prefilled syringes, which contain dry natural rubber (a derivative of latex).

Must be administered by a healthcare professional, use a 27 gauge needle to remove and inject the entire contents of the vial; do not re-enter vial, IM or IV, administer SC in upper arm, upper thigh, or abdomen, give calcium and vitamin D as needed to treat or prevent hypocalcemia, avoid vigorous shaking of vial/syringe, single dose or discard vial after entry.